{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:53Z","timestamp":1782337253269,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tice.2026.103502","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:49:52Z","timestamp":1774630192000},"page":"103502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Treatment of acute myeloid leukemia using CD3\/CD123 bispecific antibody-engaged \u03b3\u03b4T cells in a mouse xenograft model"],"prefix":"10.1016","volume":"101","author":[{"given":"Yanyun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3982-8430","authenticated-orcid":false,"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2026.103502_bib1","article-title":"CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies","volume":"12","author":"Achi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tice.2026.103502_bib2","series-title":"Seminars in Oncology","article-title":"The dual effect of interferon-\u03b3 in acute myeloid leukemia: a narrative review","author":"Angelo","year":"2025"},{"key":"10.1016\/j.tice.2026.103502_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tice.2026.103502_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1945803","article-title":"Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment","volume":"10","author":"Bonnevaux","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tice.2026.103502_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1161067","article-title":"The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions","volume":"14","author":"Carlini","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tice.2026.103502_bib6","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00262-022-03144-1","article-title":"Interleukin-12 situ cancer vaccine component a review","volume":"71","author":"Cheng","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tice.2026.103502_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tice.2026.103502_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40364-025-00762-6","article-title":"Gamma delta T cells and their immunotherapeutic potential in cancer","volume":"13","author":"Cieslak","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.tice.2026.103502_bib9","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.tice.2026.103502_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"The Journal of the American Society of Hematology, Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tice.2026.103502_bib11","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.3390\/cimb46100686","article-title":"Interleukin-12 delivery strategies and advances in tumor immunotherapy","volume":"46","author":"Dong","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.tice.2026.103502_bib12","article-title":"Engineering \u03b3\u03b4 T cells: recognizing and activating on their own way","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tice.2026.103502_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1218082","article-title":"Engineering cytokines for cancer immunotherapy: a systematic review","volume":"14","author":"Fu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tice.2026.103502_bib14","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-021-01122-7","article-title":"Selective recruitment of \u03b3\u03b4 T cells by a bispecific antibody for the treatment of acute myeloid","volume":"35","author":"Ganesan","year":"2021","journal-title":"leukemia"},{"key":"10.1016\/j.tice.2026.103502_bib15","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3390\/biomedicines10061410","article-title":"Targeting the tumor microenvironment in acute myeloid leukemia: the future of immunotherapy and natural products","volume":"10","author":"Hino","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.tice.2026.103502_bib16","doi-asserted-by":"crossref","unstructured":"L. Jimbu, O. Mesaros, C. Popescu, A. Neaga, I. Berceanu, D. Dima, M. Gaman, M. Zdrenghea, Is there a place for PD-1-PD-L blockade in acute myeloid leukemia?,\u00a0Pharmaceuticals 14 (2021) 288.","DOI":"10.3390\/ph14040288"},{"key":"10.1016\/j.tice.2026.103502_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.tice.2026.103502_bib18","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/pharmaceutics15061600","article-title":"Emerging preclinical applications of humanized mouse models in the discovery and validation of novel immunotherapeutics and their mechanisms of action for improved cancer treatment","volume":"15","author":"Karnik","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tice.2026.103502_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.20.00475","article-title":"Immune biology of acute myeloid leukemia: implications for immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.tice.2026.103502_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: a report from the Children's Oncology Group","volume":"40","author":"Lamble","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2026.103502_bib21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/hematology.2023000435","article-title":"Managing side effects: guidance for use of immunotherapies in multiple myeloma","volume":"2023","author":"Liang","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.tice.2026.103502_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12967-024-05327-z","article-title":"\u03b3\u03b4 T cells and the PD-1\/PD-L1 axis: a love\u2013hate relationship in the tumor microenvironment","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tice.2026.103502_bib23","doi-asserted-by":"crossref","unstructured":"M. Liu, M. Yang, Y. Qi, Y. Ma, Q. Guo, L. Guo, C. Liu, W. Liu, L. Xiao, Y. Yang, Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target, Frontiers in Immunology 16 (2025) 1627161.","DOI":"10.3389\/fimmu.2025.1627161"},{"key":"10.1016\/j.tice.2026.103502_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1480191","article-title":"Gamma delta T cells in cancer therapy: from tumor recognition to novel treatments","volume":"11","author":"Luo","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.tice.2026.103502_bib25","doi-asserted-by":"crossref","unstructured":"X. Luo, Y. Lv, J. Yang, R. Long, J. Qiu, Y. Deng, G. Tang, C. Zhang, J. Li, J. Zuo, Gamma delta T cells in cancer therapy: from tumor recognition to novel treatments, Front. Med.11 (2024b) 1480191.","DOI":"10.3389\/fmed.2024.1480191"},{"key":"10.1016\/j.tice.2026.103502_bib26","article-title":"A close look at current \u03b3\u03b4 T-cell immunotherapy","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tice.2026.103502_bib27","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.3390\/cancers16233974","article-title":"Inflammation and related signaling pathways in acute myeloid leukemia","volume":"16","author":"Naji","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tice.2026.103502_bib28","doi-asserted-by":"crossref","unstructured":"D. Nguyen, F. Ravandi, S.A. Wang, J.L. Jorgensen, W. Wang, K.S. Chien, G. Montalban-Bravo, G.C. Issa, A. Maiti, Y.A. Valero, A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-positive AML,\u00a0Blood 142 (2023) 322.","DOI":"10.1182\/blood-2023-190693"},{"key":"10.1016\/j.tice.2026.103502_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.mocell.2025.100177","article-title":"Human \u03b3\u03b4 T cells in the tumor microenvironment: key insights for advancing cancer immunotherapy","volume":"48","author":"Park","year":"2025","journal-title":"Mol. Cells"},{"key":"10.1016\/j.tice.2026.103502_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.tice.2026.103502_bib31","article-title":"Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies","volume":"12","author":"Rao","year":"2024","journal-title":"J. Immunotherap. Cancer"},{"key":"10.1016\/j.tice.2026.103502_bib32","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","article-title":"Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia","volume":"7","author":"Ravandi","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.tice.2026.103502_bib33","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood.2022017795","article-title":"Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells","volume":"141","author":"Rimando","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tice.2026.103502_bib34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","article-title":"Interleukin-10 in cancer immunotherapy: from bench to bedside","volume":"9","author":"Salkeni","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.tice.2026.103502_bib35","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1038\/s41467-025-63069-y","article-title":"The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS","volume":"16","author":"Schmitt","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tice.2026.103502_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.tice.2026.103502_bib37","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.4049\/jimmunol.0803068","article-title":"IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V\u03b39V\u03b42 T cells for adoptive immunotherapy","volume":"182","author":"Thedrez","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.tice.2026.103502_bib38","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1182\/blood-2024-205837","article-title":"Prognostic significance of CD123 expression in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"144","author":"Tiu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tice.2026.103502_bib39","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","article-title":"Contemporary management of acute myeloid leukemia: a review","volume":"10","author":"Venugopal","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tice.2026.103502_bib40","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tice.2026.103502_bib41","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/jcm8081261","article-title":"Antibody therapies for acute myeloid leukemia: unconjugated, toxin-conjugated, radio-conjugated and multivalent formats","volume":"8","author":"Williams","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tice.2026.103502_bib42","first-page":"11753","article-title":"A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 x CD3 bispecific Dart\u00ae molecule, in patients with relapsed or refractory CD123-positive (+) hematologic malignancies","volume":"140","author":"Winer","year":"2022","journal-title":"Am. Soc. Hematol. Wash. DC"},{"key":"10.1016\/j.tice.2026.103502_bib43","article-title":"Potential of gamma\/delta T cells for solid tumor immunotherapy","volume":"15","author":"Zhu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tice.2026.103502_bib44","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816626001953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816626001953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:53:04Z","timestamp":1778727184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816626001953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S0040816626001953"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2026.103502","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of acute myeloid leukemia using CD3\/CD123 bispecific antibody-engaged \u03b3\u03b4T cells in a mouse xenograft model","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2026.103502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103502"}}